Today, the U.S. Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph drug products for the ...

The committee concluded that current evidence did not support the recommended doses of the ingredient in OTC products for a variety of drugs, including cold, cough, allergy, bronchodilator, and ...

Clenbuterol has not been approved by the U.S. Food and Drug Administration (FDA) as an ingredient for any drugs for humans, ...

The Bronchodilator Drugs market in Puerto Rico is anticipated to witness a significant growth in revenue, with projections indicating that it will reach a staggering US$10.15m by 2024. This ...

A nebulizer is a small device that converts liquid medication into a mist, allowing it to be inhaled to relieve breathing ...

The Bronchodilator Drugs market in South Korea is forecasted to achieve a revenue of US$0.37bn in 2024. It is expected to exhibit a compound annual growth rate (CAGR) of 3.99% from 2024 to 2029 ...

A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...

Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. There is neither specific evidence that clearly ...

Increased risk of serotonin syndrome with serotonergic drugs (eg, SSRIs ... of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.